CoLucid Pharmaceuticals to Attend the BIO-Europe 2012 Meeting in Hamburg, Germany
<0> CoLucid Pharmaceuticals, Inc.Kathy Kelly, 919-649-6184 </0>
, a privately held biopharmaceutical company, announced today that Thomas P. Mathers, Chief Executive Officer, will be attending the 18 Annual International Partnering Conference held at the CCH Congress Center in Hamburg, Germany from November 12-14, 2012.
Mr. Mathers, along with Linda Hogan, Vice President of Business Development, will be meeting with potential partners to discuss the most recent clinical and regulatory milestones achieved by CoLucid for lasmiditan as well as highlights from recently completed market research.
“We have just completed two key market research activities—the first study examines the percentage of migraine patients in the United States who have concomitant risk factors for cardiovascular disease or diagnosed disease, and further quantifies their level of risk of suffering a cardiovascular event,” said Mr. Mathers. He continues, “The second market research study focuses on managed care organizations and their potential positioning of lasmiditan. Payers were very positive regarding lasmiditan’s development for migraine patients who do not respond to triptan therapy or those who have risk factors for cardiovascular disease where triptan therapy may not be appropriate.”
is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies. Lasmiditan is a member of a novel drug class called “ditans” and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal pathway. Lasmiditan does not interact with vasoconstrictor 5-HT1B receptors activated by triptans.
Six clinical studies have been successfully completed, including a Phase 2b double blind, placebo controlled, oral, dose ranging study treating a single migraine attack. In this Phase 2b study of 391 patients, lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours after dosing (p<0.0001). Separation of individual doses from placebo was seen as early as 30 minutes after dosing. Lasmiditan also achieved secondary endpoints, including relief of nausea, photophobia and phonophobia. Importantly, because there were no drug-related cardiovascular adverse effects in the previous clinical studies, CoLucid expects the pivotal Ph 3 studies to confirm that lasmiditan’s side effect profile is highly differentiated from triptans and ergot derivatives.
CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for CNS disorders. The company’s investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. For more information, please visit CoLucid at .